mAbxience | Our successful story

Our
successful story

  • 2021

    • CHMP positive opinion for our MB02 bevacizumab biosimilar.
    • Manufacture of the AstraZeneca/Oxford Covid19 Vaccine.

  • 2020

    • New state-of-the-art mAbxience biomanufacturing facility opening in Argentina.
    • MB02 Bevacizumab Global regulatory submission.
    • Commercial presence via B2B partners in more than 100 markets.
    • 3 years of recognized safety standard OHSAS 18001:2007 Certification.

  • 2019

    • New partnerships in EU, Japan, Russia, Canada and other key markets.
    • Partnered worlwide with MB02 bevacizumab biosimilar.

  • 2018

    • Alliances with leading pharma companies in EU, USA, and Australia.
    • “Business Development of the Year” Award 2018 by GGBA.

  • 2017

    • EMA GMP certification granted to mAbxience Spain.
    • First successful Scientific Advices with EMA and FDA.
    • Expansion of global access of MB01 rituximab & MB02 bevacizumab.

  • 2016

    • First launch of MB02 bevacizumab (Bevax®, Argentina).
    • “Biosimilar Initiative of the Year” Award 2016 by GGBA.
    • Global consortium established for the development of MB05 palivizumab*.

  • 2015

    • mAbxience Spain biomanufacturing and R&D center: inauguration.

  • 2014

    • Acquisition of Genhelix, a Spanish biotech R&D center becoming mAbxience scientific and operational hub.
    • First launch of MB01 rituximab (Novex®, Argentina).

  • 2012

    • mAbxience Argentina biomanufacturing facility: inauguration.

  • 2010

    • Established in Europe.
    • Acquisition of PharmaADN: mAbxience Argentina R&D platform.

CHMP: The Committee for Medicinal Products for Human Use

GMP: Good Manufacturing Practices

EMA: European Medicines Agency

FDA: US Food Drug Administration

GGBA: Global Generics & Biosimilar Awards

* Programme endorsed by the World Health Organization (WHO) for the treatment of Respiratory Sincitial Virus in pediatric population